717134-65-1

Basic information

• Product Name: N-allyloxy-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylamino]-benzamide
• Synonyms: N-allyloxy-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylamino]-benzamide
• CAS NO: 717134-65-1
• Molecular Weight: 411.463
• Mol File: 717134-65-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-allyloxy-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylamino]-benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-allyloxy-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylamino]-benzamide(717134-65-1)
• EPA Substance Registry System: N-allyloxy-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylamino]-benzamide(717134-65-1)

Safety Data

• Hazardous Substances Data: 717134-65-1(Hazardous Substances Data)

Upstream product

• 717134-63-9 2-[3-(2-pyridin-2-yl-vinyl)-1H-indazol-6-ylamino]-benzoic acid 
• 38945-21-0 O-allylhydroxylamine hydrochloride 

Relevant articles and documents

2-(1H-INDAZOL-6-YLAMINO)-BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTALMIC DISEASES

Indazole compounds that modulate and/or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating ophthalmic diseases and cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma,rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.